Matwings, an AI-driven full-stack protein R&D platform company, secures over RMB 200 million in Series A+ funding

Recently, Matwings, an AI-driven full-stack protein R&D platform company, has completed a Series A+ financing round exceeding RMB 200 million. This round was jointly led by Kunlun Capital (a subsidiary of China National Petroleum Corporation), existing shareholder Yonghua Capital, and the Shanghai Future Industries Fund. It also saw participation from SDIC Fund, Xingongxiao Capital, Parmercare, and Fortera Capital, with strong follow-on investment from existing shareholders including Qiming Venture Partners, GSR United Capital (Runpu Medical Fund), and 3E Bioventures.

About Matwings

Matwings is a pioneering AI-driven, full-stack protein R&D platform. By constructing a proprietary, large-scale protein sequence dataset and label library—a unique asset in the industry—Matwings has developed a foundational large model for protein design. This enables the precise design of functional proteins that directly address specific industrial application needs.

With its proprietary protein large model as the core engine, Matwings has developed a scientific research agent and automated experimental equipment, creating a comprehensive, full-stack AI protein R&D platform. This platform covers the entire development lifecycle—from market, literature, and patent research, through molecular design, small-scale validation, and pilot process optimization, all the way to production scale-up. By deeply integrating AI into practical industrial application scenarios, Matwings aims to transcend the current cognitive boundaries of human experts, enabling faster and better development of a wide range of biological products that utilize proteins as their fundamental building blocks. These include applications in innovative drugs, broader healthcare, agriculture, functional foods, and bio-based materials.